.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Cholestatic liver diseases (CLD), such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), significantly impair patient quality of life. These conditions often lead to debilitating sickness-behavior symptoms, including chronic fatigue, cognitive decline, and anxiety. Recent neuroimaging studies have highlighted structural changes in the thalamus of these patients. Importantly, research suggests that TNF neutralization cholestasis thalamus pathways may be central to managing these neurological complications. Researchers are now exploring how systemic inflammation directly alters brain transcriptomics.
A recent study utilized a bile duct ligation (BDL) mouse model to investigate the mechanistic link between liver injury and brain health. MRI analysis revealed that BDL mice suffered from reduced thalamic volume compared to healthy controls. Furthermore, RNA-seq transcriptomic signatures indicated a massive shift in molecular activity. These changes suggested the inhibition of cellular growth, impaired neurite formation, and enhanced apoptosis within the thalamus. Consequently, these structural and functional alterations likely drive the behavioral symptoms observed in clinical settings.
Systemic TNF acts as a primary regulator of liver-to-brain communication. Therefore, scientists administered anti-TNF antibodies to neutralize systemic TNF in the BDL model. This intervention yielded significant results, as the therapy effectively attenuated the BDL-associated transcriptomic changes. Specifically, TNF inhibition enhanced gene expression in pathways dedicated to neurotransmission and neuron survival. While myelination pathways remained largely unchanged, the overall structural machinery showed remarkable recovery. Resultantly, this suggests that targeting TNF may represent a novel approach to treat the neurological burden of liver disease.
Currently, treatment options for the fatigue and cognitive symptoms associated with CLD remain limited. However, this study provides a molecular foundation for the use of TNF inhibitors in a hepatology context. Notably, neutralizing systemic inflammation might prevent the progressive thalamic atrophy that correlates with symptom severity. Clinicians should monitor emerging data on biological therapies that bridge the gap between systemic inflammation and central nervous system health.
Cholestasis triggers systemic inflammation, specifically increasing TNF levels. These cytokines cross or communicate through the blood-brain barrier, altering the transcriptomic signature of the thalamus and disrupting neural signaling, which leads to fatigue and cognitive impairment.
According to recent research, TNF neutralization significantly improves pathways related to neurotransmission and neuron survival. However, some changes, such as alterations in myelination pathways, may remain unaffected by this specific intervention.
No, anti-TNF therapy for fatigue in PBC or PSC is currently in the experimental and research stages. While mouse models show promise, clinical trials are necessary to determine safety and efficacy in human populations.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
New research identifies how TNF neutralization mitigates thalamic transcriptomic changes in cholestatic liver injury, potentially addressing fatigue symptom...
4 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
